BillionToOne, Inc.
BLLN
Updated: 24/09/2026, 12:06:11
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
No summaries found.
- Share price
- $114.42
- Market cap
- $5.26B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Oguzhan Atay
- Employees
- 713
- IPO date
- 06/11/2025
- Beta
- 0.34009698
- Last dividend
- $0.00
- Day range
- $113.55 – $117.17
- 52-week range
- $61.96 – $150.44
- 1-day performance
- -1.42%
- 1-year performance
- 84.67%
- Current drawdown (1Y)
- -23.94%
- CIK
- 0002070849
- CUSIP
- 090168105
- ISIN
- US0901681058
- Created
- 07/12/2025, 03:02:13
- Last update
- 24/09/2026, 12:06:11
Track BillionToOne, Inc. with an AI analyst
See which prediction-market events move BLLN, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Baron Health Care Fund Q1 2026 Portfolio Activity
Seeking Alpha • STOCK • 27/05/2026, 17:16:00
Does BillionToOne (BLLN) Have the Potential to Rally 37% as Wall Street Analysts Expect?
Zacks Investment Research • STOCK • 25/05/2026, 12:56:14
BillionToOne (BLLN) Reports Q1 Earnings: What Key Metrics Have to Say
Zacks Investment Research • STOCK • 06/05/2026, 22:02:09
BillionToOne Launches Unity Confirm™: A category-defining test that bridges the gap between screening and invasive diagnostics
PRNewsWire • STOCK • 01/05/2026, 21:00:00
BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology
PRNewsWire • STOCK • 02/04/2026, 11:00:00
BillionToOne, Inc. (BLLN) Q4 2025 Earnings Call Transcript
Seeking Alpha • STOCK • 06/03/2026, 18:45:58
BillionToOne: Delivering And Lagging At The Same Time
Seeking Alpha • STOCK • 06/03/2026, 14:08:23
BillionToOne (BLLN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates
Zacks Investment Research • STOCK • 04/03/2026, 20:01:08
BillionToOne Stock at $89: Why a New $19.1 Million Position Could Matter Now
The Motley Fool • STOCK • 14/02/2026, 12:49:36
BillionToOne Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select®
PRNewsWire • STOCK • 10/02/2026, 10:00:00
BillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal Care
PRNewsWire • STOCK • 09/02/2026, 13:29:00